Moscow Medical Academy Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2002
NCT00715572
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Alternative names

Moscow Medical Academy, Department of Endocrinology | Moscow Medical Academy n.a. I.M. Sechenov

Active Ingredients

Drugs in Phase 3 Trials (1)

naltrexone (revia) (1 trial)

Drugs in Other Trials (2)

dextrothyroxine (choloxin) (1 trial)

liothyronine (cytomel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Opioid-Related Disorders (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3